- CITATIONS: 1
|Application ||WB, E|
|Calculated MW||56259 Da|
|Antigen Region||382-411 aa|
|Other Names||E3 ubiquitin-protein ligase TRIM68, 632-, RING finger protein 137, SSA protein SS-56, SS-56, Tripartite motif-containing protein 68, TRIM68, GC109, RNF137, SS56|
|Target/Specificity||This TRIM68 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 382-411 amino acids from the C-terminal region of human TRIM68.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TRIM68 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||GC109, RNF137, SS56|
|Function||Functions as a ubiquitin E3 ligase. Acts as a coactivator of androgen receptor (AR) depending on its ubiquitin ligase activity.|
|Cellular Location||Cytoplasm, perinuclear region. Nucleus. Note=Colocalized with AR in nucleus|
|Tissue Location||Widely expressed. Expressed at high levels in prostate cancer cell lines. Up-regulation could be restricted to androgen-dependent cells.|
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene contains a RING finger domain, a motif present in a variety of functionally distinct proteins and known to be involved in protein-protein and protein-DNA interactions. This gene is expressed in many cancer cell lines. Its expression in normal tissues, however, was found to be restricted to prostate. This gene was also found to be differentially expressed in androgen-dependent versus androgen-independent prostate cancer cells.
Malhotra, A., et al. Diabetes Metab. Res. Rev. 25(8):740-747(2009)
Miyajima, N., et al. Cancer Res. 68(9):3486-3494(2008)
Chang, G.T., et al. Eur. J. Cancer 37(16):2129-2134(2001)
Billaut-Mulot, O., et al. J. Clin. Invest. 108(6):861-869(2001)
Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.